~~<i id='7AC9FC7A8F'><strike id='7AC9FC7A8F'><tt id='7AC9FC7A8F'><pre id='7AC9FC7A8F'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

hotspot

author：explore 2025-08-31 01:56:29 - browse：84

Adam's take main illustration — Molly Ferguson/STAT

Shares of Apellis Pharmaceuticals are rebounding, driven by a growing belief among some investors that the serious safety issue that has derailed Syfovre, the company’s eye disease treatment, is receding.

Declaring the crisis over is premature, but that could change with more uneventful weeks. Apellis has been a takeout target before, and may be again, at an acquisition price nearly twice its current market value.

Apellis shares rose 32% last week, with most of the gains coming Friday on heavy trading volume. The reason: There have been no new cases of retinal occlusive vasculitis, or ROV, reported in people receiving injections of Syfovre.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： Court strikes down limits on filming of police in Arizona

focus

Wikipedia

focus

knowledge

Sen.ElizabethWarren(D-Mass.)J.ScottApplewhite/APWASHINGTON—Sen.ElizabethWarren(D-Mass.)islaunchingaf

WSS

What to know about Saharan dust affecting the US and how it can affect health

Gene therapy has helped boys walk. Can scientists keep it that way?

As Taiwan prepares for anti

Contact tracing may help avoid another lockdown. Can it work in the U.S.?

With FDA staff opposed to Sarepta therapy, top official intervened

Vatican is moving ahead with plan to reunite Ukrainian children taken to Russia with their families

knowledge

hotspot

focus

New air purifier tech could be key to improving indoor air quality

With FDA staff opposed to Sarepta therapy, top official intervened

Anesthesiologist group: stop taking Ozempic before surgery

New guidelines on severe brain injury complicate already difficult decisions

New air purifier tech could be key to improving indoor air quality

Our daughter's deadly disease: trisomy 18. We wanted to protect her

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

With FDA staff opposed to Sarepta therapy, top official intervened

Medical records are filled with copy

WATCH: Why do fingernails fall off when they're damaged?

focus

Southern California school board OKs curriculum after Gov. Gavin Newsom threatened a $1.5M fine

Artificial intelligence advances fuel industry trying to preserve loved ones after death

In new study, freeze

Paxlovid study fails to answer questions over benefit for broader groups

Vatican is moving ahead with plan to reunite Ukrainian children taken to Russia with their families

The strategy behind pharma's lawsuits over drug pricing reform

focus

Wikipedia

focus

knowledge